Targets › FCRL5
3 programs from 2 companies in 10 trials: 4 Phase 1, 3 Phase 3, 3 Phase 2; Oncology, Neurology, Immunology; next expected readout Nov 2026.
Plays an important role in B-cell response to antigen that acts both as a negative or positive coreceptor. Inhibits B-cell receptor (BCR) signaling in the absence of CR2 stimulation but engagement with CR2 and the BCR lead to a superior calcium response compared to CR2 and BCR costimulation. (UniProt, Q96RD9)
Open in Phaseline: the race on FCRL5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| argenx | Empasiprubart FcRn antagonist | FCRN, FCRL5 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy (MMN); Dermatomyositis; AChR-Ab Seropositive Generalized Myasthenia Gravis … | Nov 2026 |
| Xuzhou Medical University | anti-FcRL5 CAR-T anti-FcRL5 CAR-T cell therapy | FCRL5 | Phase 1 | Multiple Myeloma | Jan 2027 |
| Xuzhou Medical University | anti-BCMA/FcRL5 CAR-T dual-targeted CAR-T cell therapy targeting BCMA and FcRL5 | BCMA, FCRL5 | Phase 1 | Multiple Myeloma | Dec 2027 |
Chronic Inflammatory Demyelinating Polyneuropathy (2) Multifocal Motor Neuropathy (MMN) (2) AChR-Ab Seropositive Generalized Myasthenia Gravis (2) Multiple Myeloma (2) Dermatomyositis (1) Healthy Volunteers (1)
other (2), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.